Clinical Trial Update: Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating inhaled nitric oxide for SARS and COVID-19 completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• Nitric oxide inhalation (nitric oxide)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: SARS (Severe Acute Respiratory Syndrome), Coronavirus | Phase 2 | Status: COMPLETED | Results posted: 2026-04-01